The U.S. veterinary medicine market size is anticipated to reach USD 21.80 billion by 2030 and is projected to grow at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence rates of zoonotic diseases, increased livestock population, growing focus on preventive care, advancements in pet medicine and increasing pet ownership are the major factors contributing to the market growth. According to the March 2023 report released by the American Pet Products Association (APPA), dogs are the most popular pets in the U.S., with 65.1 million households owning a dog. Cats come in second with 46.5 million households, followed by freshwater fish with 11.1 million households.
The livestock population has grown significantly, leading to an increase in zoonotic diseases and chronic diseases. This has led to a growing emphasis on preventive healthcare measures to maintain the health and productivity of animals. Moreover, advancements in technology have revolutionized veterinary medicine by enhancing diagnostic capabilities, treatment options, and medical devices, thereby improving the quality of animal care.
Request a free sample copy or view report summary: U.S. Veterinary Medicine Market Report
Based on products, the pharmaceuticals segment led the market with the largest revenue share of 67.6% in 2023, owing to growing investments in research and development and advancements in the field of medicine
Based on the animal type, the production animals segment held the market with largest revenue share of 58.5% in 2023, due to an increasing demand for animal protein due to population growth and globalization of livestock production. Companion animals in animal type segment are anticipated to witness fastest CAGR over the forecast period
Based on route of administration, the injectable segment dominated the market in 2023 and oral segment is anticipated to witness a significant growth in CAGR over the forecast period, owing to an increasing pet ownership and focus on preventive healthcare
Based on distribution channel, the veterinary hospitals & clinics segment held the majority of the market share in 2023 and e-commerce segment is expected to grow at the fastest CAGR over forecast period
In February 2024, Merck & Co., Inc. announced the signing of a definitive agreement to acquire the aqua business of Elanco, which includes an innovative portfolio of medications and vaccines, food, and supplements for aquatic animals
Grand View Research has segmented the U.S. veterinary medicine market based on the product, animal type, route of administration, and distribution channel:
U.S. Veterinary Medicine Product Outlook (Revenue, USD Million, 2018 - 2030)
Biologics
Vaccines
Modified/ Attenuated live
Inactivated (Killed)
Other Vaccines
Other Biologics
Pharmaceuticals
Parasiticides
Anti-infectives
Anti-inflammatory
Analgesics
Others
Medicated Feed Additives
U.S. Veterinary Medicine Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
Production Animals
Poultry
Pigs
Cattle
Sheep & Goats
Others
Companion Animals
Dogs
Cats
Horses
Others
U.S. Veterinary Medicine Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Oral
Injectable
Topical
Other Routes
U.S. Veterinary Medicine Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Veterinary Hospitals & Clinics
E-commerce
Offline Retail Stores
Others
List of Key Players in the U.S. Veterinary Medicine Market
Zoetis Services LLC
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
Elanco
Ceva
Phibro Animal Health Corporation
Bimeda Corporate
IDEXX
Vetbiologics
Neogen Corporation
ADM
Kindred Biosciences, Inc.
Cargill, Incorporated
"The quality of research they have done for us has been excellent..."